Literature DB >> 8957019

Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals.

K Nishiyama1, S Murayama, J Goto, M Watanabe, H Hashida, S Katayama, Y Nomura, S Nakamura, I Kanazawa.   

Abstract

Machado-Joseph disease (MJD) is an autosomal dominant disorder characterized pathologically by spinocerebellar degeneration. Recently, an expansion of CAG repeat in a gene located at the chromosome 14q32.1 was found to be responsible for the disease. Here, we investigated in situ the expression of the MJD gene (MJD1) in the central nervous systems of normal and affected individuals and in rat brains. This gene was expressed in all regions of rat and human normal brains with certain regional variations. MJD1 was transcribed preferentially in neurons, although low levels of MJD1 mRNA were also observed in glial cells. Neurons susceptible to degeneration in MJD expressed MJD1 but not selectively. In the affected brains, the MJD1 mRNA distribution and amount in all the areas examined were similar in patients and controls. In addition, the cellular MJD1 mRNA level correlated neither with clinical severity nor expanded length. Our study showed that the expression levels of trinucleotide repeats in MJD patients and normal controls did not differ, indicating that the pathogenesis of MJD may involve direct toxicity to vulnerable subsets and/or region-specific cofactors of MJD proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957019     DOI: 10.1002/ana.410400514

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

Review 1.  Machado-Joseph disease/spinocerebellar ataxia type 3.

Authors:  Henry Paulson
Journal:  Handb Clin Neurol       Date:  2012

2.  Flanking sequences profoundly alter polyglutamine toxicity in yeast.

Authors:  Martin L Duennwald; Smitha Jagadish; Paul J Muchowski; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

Review 3.  Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).

Authors:  Veronica F Colomer Gould
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 4.  Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.

Authors:  Veronica F Colomer Gould
Journal:  NeuroRx       Date:  2005-07

5.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

6.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

Review 7.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Casein kinase 2 interacts with and phosphorylates ataxin-3.

Authors:  Rui-Song Tao; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-10       Impact factor: 5.203

9.  A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.

Authors:  Veronica F Colomer Gould; Daniel Goti; Donna Pearce; Guillermo A Gonzalez; Hong Gao; Mario Bermudez de Leon; Nancy A Jenkins; Neal G Copeland; Christopher A Ross; Dale R Brown
Journal:  Neurobiol Dis       Date:  2007-06-13       Impact factor: 5.996

10.  Autophagy Promoted the Degradation of Mutant ATXN3 in Neurally Differentiated Spinocerebellar Ataxia-3 Human Induced Pluripotent Stem Cells.

Authors:  Zhanhui Ou; Min Luo; Xiaohua Niu; Yuchang Chen; Yingjun Xie; Wenyin He; Bing Song; Yexing Xian; Di Fan; Shuming OuYang; Xiaofang Sun
Journal:  Biomed Res Int       Date:  2016-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.